OncoZenge Investor Relations Material
Latest events
Q2 2025
21 Aug, 2025
Q1 2025
15 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from OncoZenge
Access all reports
OncoZenge AB (publ), a pharmaceutical company, develops healthcare products for cancer supportive care. Its products include Palonosetron Fertiginject, an antiemetic product developed and launched in the Nordics; and Yserenate, a pharmaceutical preparation that is used for the treatment of hyperammonemia in patients with N-acetylglutamate synthase deficiency, as well as for the treatment of hypophosphatemia in patients with chronic kidney disease. The company was founded in 2020 and is headquartered in Bromma, Sweden.
Latest articles
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
Ticker symbol
ONCOZ
Country
🇸🇪 Sweden